This week's innovators to know roundup includes Durg Kumar of Knightsgate Ventures, Rand Stephens of Avison Young, and Shail Sinhasane of Mobisoft. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators across industries — from commercial real estate to venture capital.

Durg Kumar, managing partner at Knightsgate Ventures

Durg Kumar — along with his New York-based business partner Allen Bryant — join the Houston Innovators Podcast to discuss their second fund. Photos courtesy

As Durg Kumar enters into his venture capital firm's second fund, his focus is not diverted from Knightsgate Ventures' existing portfolio in this unprecedented time. Throughout the pandemic, Houston-based Knightsgate has been offering support to these startups.

"Now's a good time to retrench and focus on building product," Kumar says, "so that in 2021 when travel restrictions ease, then you've got your refined product to go out and take it to the customers."

Kumar and Allen Bryant, the VCs other partner, joined the Houston Innovators Podcast to discuss their second fund and more. Click here to read more and stream the episode.

Rand Stephens, managing director of Avison Young's Houston office

Rand Stephens discusses COVID-19's effect on office and innovation spaces. Durg Kumar (left) and Allen Bryant, partners at Knightsgate Ventures, join the Houston Innovators Podcast to discuss their second fund. Photos courtesy

Since the 1980s, Houston has been increasing focus on diversifying its economy from oil and gas. Rand Stephens has observed this and noted that new innovation centers rising — like The Ion and A&M's new hub in the TMC — are indicators of progress.

"Houston is an incredible diverse city. We have unlimited talent from an engineering standpoint, and I think those types of projects bode well for keeping and attracting top tech talent. I think that's really the key," he says.

He discusses this progress and the effect of the pandemic on CRE in a Q&A. Click here to read more.

Shail Sinhasane, CEO of Mobisoft

This Houston entrepreneur created a new tool can be used to coordinate responsible rides for passengers infected with COVID-19. Photo courtesy

As the pandemic's effects continue to reverberate into aspects of daily life, a Houston software company has pivoted its technology to create an app that can safely transport COVID-19 patients to their quarantine location.

Mobisoft announced the launch of NEMT Pulse, a non-emergency medical transportation app to be used by schools, community health centers, hospitals, and more to easily facilitate isolated rides.

"We pivoted our NEMT software that could be implemented to safely meet the needs of those affected by COVID-19," says Shail Sinhasane, CEO of Mobisoft, in a news release. "This app provides a solution to ensure individuals who have tested positive can get to their quarantine location with one less thing to worry about." Click here to read more.

Rand Stephens, managing director of Avison Young's Houston office, discusses COVID-19's effect on office and innovation spaces. Photo courtesy of Avison Young

Houston real estate expert shares why now's the time for the city's innovation ecosystem to emerge

Q&A

Rand Stephens has been in Houston since the '80s, and he's seen the city evolve from having an economy heavily dominated by oil and gas to a city focused on diversification of industry.

Now, as a technology and innovation ecosystem is emerging with new startup and lab space being developed, Houston is on a good path — even in light of the effects of the pandemic.

"I think that Houston is a very vibrant place and it always has been. It's very entrepreneurial, and it will adjust to the new environment," says Stephens, who's principal at Avison Young and the founding managing director of the company's Houston office.

Stephens discussed the importance of new developments and the effect of the pandemic on the commercial real estate industry in an interview with InnovationMap.

InnovationMap: Why is the timing right for Houston's innovation ecosystem to emerge?

Rand Stephens: Since the '80s, there's been a real emphasis within the city to diversify. Trying to do new things is always difficult because a lot of it has to do with timing — it has to make sense economically. Innovation is a hot thing right now, more so than ever. As a city or company, if you're not constantly innovating, you're going to get left behind.

From a real estate standpoint, we've really had an abundance of low-cost space in an environment that is very entrepreneurial.

IM: Why are emerging innovation campuses like The Ion and Texas A&M Innovation Plaza near the Texas Medical Center so important?

RS: Houston is an incredible diverse city. We have unlimited talent from an engineering standpoint, and I think those types of projects bode well for keeping and attracting top tech talent. I think that's really the key.

You have to have this kind of infrastructure to support the innovation. The more that we can do to make the city walkable and to provide connectivity to the different parts of the city, is important. It's all about the experience. And, I don't think people like getting in the car and fight traffic — I think it's that simple.

IM: Has COVID-19 affected the momentum of innovation development?

RS: It has. But, what I've seen, and it's totally anecdotal, but people are coming to grips with COVID. They are coming to grips with the risks, and, as time goes on, they will see it as a less risky disease as a vaccine and treatment become available.

These innovation spaces are going to be important for collaboration. You lose the spontaneity of innovation and collaboration if you're not around people. But, we're already seeing people in Houston returning to work.

IM: In general, how is the pandemic affecting commercial real estate?

RS: COVID is impacting the office market the most — and I think it will long term as well. There's been a trend for a long time now to use less square footage per person. I think corporations have evolved from looking at their office spaces as a place to put people to work to really trying to create an experiential environment to use the office to re-enforce their culture and brand in order to recruit top talent. COVID has accelerated that trend now.

My gut feeling on that is it's going to depend on the business. Different types of industries function differently, and the size of the business is going to depend on that too. I think the trend of using less square footage per person isn't going to go up. I don't think we're going to see companies taking more space for social distancing. I think what they'll do is give people more flexibility. I think corporates are going to say, "let's ammenitize our space and put people in places where it's experiential and a cool place to work." And I think people are OK with that.

IM: What makes Houston a good city for innovation?

RS: There are three or four reasons off the top of my head, but one is the entrepreneurial spirit and that's pervasive everywhere. Then, we have amazing infrastructure here, with talent and education. Another thing that is key is affordability. Relatively speaking, it's a very affordable city to do business in. The fourth thing would be the diversity and inclusion we have here. Houston is one of the most diverse cities in the country — and a lot of people don't know that. And I have found it to be an incredibly inclusive city. I think if you move here and you have good ideas and work hard, there's nothing to hold you back here.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston family's $20M donation drives neurodegeneration research

big impact

Neurodegeneration is one of the cruelest ways to age, but one Houston family is sharing its wealth to invigorate research with the goal of eradicating diseases like Alzheimer’s.

This month, Laurence Belfer announced that his family, led by oil tycoon Robert Belfer, had donated an additional $20 million to the Belfer Neurodegeneration Consortium, a multi-institutional initiative that targets the study and treatment of Alzheimer’s disease.

This latest sum brings the family’s donations to BNDC to $53.5 million over a little more than a decade. The Belfer family’s recent donation will be matched by institutional philanthropic efforts, meaning BNDC will actually be $40 million richer.

BNDC was formed in 2012 to help scientists gain stronger awareness of neurodegenerative disease biology and its potential treatments. It incorporates not only The University of Texas MD Anderson Cancer Center, but also Baylor College of Medicine, Massachusetts Institute of Technology (MIT) and Icahn School of Medicine at Mount Sinai.

It is the BNDC’s lofty objective to develop five new drugs for Alzheimer’s disease and related disorders over the next 10 years, with two treatments to demonstrate clinical efficacy.

“Our goal is ambitious, but having access to the vast clinical trial expertise at MD Anderson ensures our therapeutics can improve the lives of patients everywhere,” BNDC Executive Director Jim Ray says in a press release. “The key elements for success are in place: a powerful research model, a winning collaborative team and a robust translational pipeline, all in the right place at the right time.”

It may seem out of place that this research is happening at MD Anderson, but scientists are delving into the intersection between cancer and neurological disease through the hospital’s Cancer Neuroscience Program.

“Since the consortium was formed, we have made tremendous progress in our understanding of the molecular and genetic basis of neurodegenerative diseases and in translating those findings into effective targeted drugs and diagnostics for patients,” Ray continues. “Yet, we still have more work to do. Alzheimer's disease is already the most expensive disease in the United States. As our population continues to age, addressing quality-of-life issues and other challenges of treating and living with age-associated diseases must become a priority.”

And for the magnanimous Belfer family, it already is.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the founder of a new venture firm, a former astronaut and recent award recipient, and a health care innovator with fresh funding.

Zach Ellis, founder and managing partner of South Loop Ventures

Zach Ellis explains on the Houston Innovators Podcast that South Loop Ventures plans to invest in promising companies from across the country and bring them into Houston's ecosystem to grow and scale. Photo via LinkedIn

Houston has a lot of the right ingredients for commercialization and scaling up companies, so when Zach Ellis moved to town to stand up a venture capital firm that made investments in diverse founders, he decided to go about it in an innovative way.

South Loop Ventures, which Ellis launched two years ago, invests in pre-seed and seed-stage startups across health care, climatetech, aerospace, sports, and fintech. While the first handful of investments, which have already been made, are into Houston-based companies, Ellis explains on the Houston Innovators Podcast that the firm plans to invest in promising companies from across the country and bring them into Houston's ecosystem to grow and scale.

"Any investor wants to feel like they are looking at the best possible investment opportunities in which to deploy capital," Ellis says on the show. "So that's reason No. 1 to cast your net as widely as possible.

"At the same time, you want to give any investment that you make greatest chances of success," he continues. "The biggest factor of success outside of the team and the capital you give them, is the customers that they can call upon. In bringing targeted companies to Houston or connecting them with Houston, you introduce the opportunity for them to achieve rapid scale and work with world-class partners very efficiently." Read more.


Toby R. Hamilton, founder and CEO of Hamilton Health Box

Dr. Toby Hamilton has secured $10 million to grow his company. Photo via tmc.edu

A Houston company that is working on a value-based model for primary care has fresh funding to support its mission.

Hamilton Health Box announced the completion of a $10 million series A funding round led by 1588 Ventures with participation from Memorial Hermann Health System, Impact Ventures by Johnson & Johnson Foundation, Texas Medical Center Venture Fund, and the Sullivan Brothers.

The company, founded in 2019 by Dr. Toby R. Hamilton, will use the funding to fuel its expansion into rural areas to help assist those living in Health Professional Shortage Areas, or HPSAs. Read more.

Ellen Ochoa, former astronaut and center director at the NASA's Johnson Space Center

Ellen Ochoa was recognized for her leadership at NASA Johnson and for being the first Hispanic woman in space. Photo via NASA

Two astronauts recently received Presidential Medals of Freedom from President Joe Biden for their leadership in space.

Ellen Ochoa, the former center director and astronaut at the NASA's Johnson Space Center in Houston, and Jane Rigby, senior project scientist for NASA’s James Webb Space Telescope, were honored at the White House on May 3.

Ochoa spent 30 years with NASA, which included being the 11th director of JSC, deputy center director of JSC, and director of Flight Crew Operations. She served on the nine-day STS-56 mission aboard the space shuttle Discovery in 1993, and became the first Hispanic woman in space. She flew four more times to space with STS-66, STS-96, STS-110, and more.

“I’m so grateful for all my amazing NASA colleagues who shared my career journey with me,” Ochoa says in a NASA news release. Read more.

Houston health care institutions receive $22M to attract top recruits

coming to Hou

Houston’s Baylor College of Medicine has received a total of $12 million in grants from the Cancer Prevention & Research Institute of Texas to attract two prominent researchers.

The two grants, which are $6 million each, are earmarked for recruitment of Thomas Milner and Radek Skoda. The Cancer Prevention & Research Institute of Texas (CPRIT) announced the grants May 14.

Milner, an expert in photomedicine for surgery and diagnostics, is a professor of surgery and biomedical engineering at the Beckman Laser Institute & Medical Clinic at the University of California, Irvine and the university’s Chao Family Comprehensive Cancer Center

In 2013, Milner was named Inventor of the Year by the University of Texas at Austin. At the time, he was a professor of biomedical engineering at UT. One of his major achievements is co-development of the MasSpec Pen, a handheld device that identifies cancerous tissue within 10 seconds during surgical procedures.

Skoda is a professor of molecular medicine in the Department of Biomedicine at the University of Basel and the University Hospital Basel, both in Switzerland. He specializes in developing treatments for myeloproliferative neoplasms, which are a group of blood diseases including leukemia.

Other recruitment grants provided by the institute to Houston-area organizations are:

  • $4 million for recruitment of Susan Bullman to the University of Texas M.D. Anderson Cancer Center. She was an assistant professor at Seattle’s Fred Hutchinson Cancer Center, where she studied the connection between microbes and cancer.
  • $4 million for recruitment of Oren Rom to the University of Texas M.D. Anderson Cancer Center. Rom is an assistant professor of pathology and translational pathobiology at Louisiana State University Shreveport.
  • Nearly $2 million for recruitment of Lauren Hagler to conduct RNA cancer biology at Texas A&M University. She is a postdoctoral scholar in biochemistry at Stanford University.

The institute also awarded grants to five companies in the Houston area:

  • $4.7 million to 7 Hills Pharma for development of immunotherapies to treat cancer and prevent infectious diseases.
  • $4.5 million to Indapta Therapeutics for the Phase 1 trial of a cell therapy for treatment of multiple myeloma and non-Hodgkin’s lymphoma.
  • $2.75 million to Bectas Therapeutics for development of antibodies and biomarkers to overcome a type of resistance T-cell checkpoint therapy.
  • $2.69 million to MS Pen Technologies for development of technology that differentiates between normal tissue and cancerous tissue during surgery.
  • $2.58 million to Crossbridge Bio for development of an antibody-drug combination to treat certain solid tumors.